ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV)

1.33
-0.01
(-0.75%)
終値: 12月5日 6:00AM
1.33
0.00
( 0.00% )
取引時間後: 6:49AM

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
1.33
買値
1.30
売値
1.42
出来高
23,549
1.32 日の範囲 1.3669
1.12 52 週間の範囲 2.6702
時価総額
前日終値
1.34
始値
1.33
最終取引時間
06:00:00
財務取引量
US$ 31,361
VWAP
1.3317
平均取引量 (3 か月)
94,220
発行済株式数
5,896,333
配当利回り
-
PER
-0.59
1 株当たり利益 (EPS)
-2.26
歳入
4.91M
純利益
-13.32M

Plus Therapeutics Inc について

Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases.

セクター
Surgical,med Instr,apparatus
業界
Surgical,med Instr,apparatus
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Plus Therapeutics Inc is listed in the Surgical,med Instr,apparatus sector of the ナスダック市場 with ticker PSTV. The last closing price for Plus Therapeutics was US$1.34. Over the last year, Plus Therapeutics shares have traded in a share price range of US$ 1.12 to US$ 2.6702.

Plus Therapeutics currently has 5,896,333 shares in issue. The market capitalisation of Plus Therapeutics is US$7.90 million. Plus Therapeutics has a price to earnings ratio (PE ratio) of -0.59.

PSTV 最新ニュース

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec. 04, 2024...

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today...

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Single intrathecal dose of Rhenium (186Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation...

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal...

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes...

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented...

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for...

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.075.555555555561.261.4151.23488361.32394729CS
40.075.555555555561.261.491.121678291.30326815CS
12-0.02-1.481481481481.351.941.12942201.38233835CS
26-0.96-41.92139737992.292.67021.12746901.53605839CS
52-0.46-25.69832402231.792.67021.12648001.72467448CS
156-16.52-92.549019607817.8532.40.969480736512.12152453CS
260-30.77-95.856697819332.1101.250.969478715222.19557928CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MIGIMawson Infrastructure Group Inc
US$ 1.13
(66.15%)
2.44M
PRFXPainReform Ltd
US$ 4.2995
(60.43%)
3.14M
VRNTVerint Systems Inc
US$ 31.10
(19.75%)
263.3k
MTEMMolecular Templates Inc
US$ 0.39
(15.83%)
584.34k
FIVEFive Below Inc
US$ 116.84
(11.31%)
977.16k
BLUEbluebird bio Inc
US$ 0.4325
(-41.26%)
11.89M
UPXIUpexi Inc
US$ 4.31
(-27.81%)
96.71k
CYCNCyclerion Therapeutics Inc
US$ 5.45
(-14.17%)
883.01k
HTOOFusion Fuel Green PLC
US$ 0.4494
(-13.58%)
541.06k
RENBRenovaro Inc
US$ 1.10
(-12.00%)
6.84k
BLUEbluebird bio Inc
US$ 0.4325
(-41.26%)
11.89M
PEVPhoenix Motor Inc
US$ 0.3278
(-11.02%)
9.26M
SMXSMX Security Matters Public Company
US$ 0.38
(-5.00%)
6.79M
SVMHSRIVARU Holding Ltd
US$ 0.0241
(2.55%)
3.3M
PRFXPainReform Ltd
US$ 4.2995
(60.43%)
3.14M

PSTV Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock